{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-048036","form_type":"8-K","ticker":"AXSM","cik":"0001579428","company_name":"Axsome Therapeutics, Inc.","filed_at":"2025-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.860522+00:00","generated_at":"2026-05-24T00:47:51.976441+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Axsome's solriamfetol misses primary endpoint in Phase 3 MDD trial; subgroup with severe EDS shows improvement","bullets":["Primary endpoint (change in MADRS total score) not met in overall MDD population.","In prespecified subgroup with severe EDS (ESS ≥16), solriamfetol showed greater improvements vs placebo on multiple measures.","Axsome plans to initiate a Phase 3 trial in MDD with EDS in 2025 based on subgroup results.","Safety profile consistent with established safety of solriamfetol; no new signals.","Approximately 50% of MDD patients experience EDS, highlighting unmet need."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-048036","json":"https://secwatch.observer/filing/0000950170-25-048036.json","markdown":"https://secwatch.observer/filing/0000950170-25-048036.md","text":"https://secwatch.observer/filing/0000950170-25-048036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1579428/000095017025048036/0000950170-25-048036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1579428/000095017025048036/axsm-20250401.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T00:47:51.976441+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}